Skip to main content

Advertisement

Fig. 5 | Molecular Cancer

Fig. 5

From: MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

Fig. 5

a - Disease-free survival (DFS) curves based on pathological stage (upper left panel) and Gleason score (upper right panel), and miR-129-2 methylation levels (lower panel) in Cohort #1. b - Disease-free survival (DFS) curves based on clinical stage (upper left panel) and Gleason score (upper right panel), miR-34b/c (lower left) and miR-129-2 (lower right) methylation levels in Cohort #2

Back to article page